The new patent concerns a method for treating autism spectrum disorder and neurodevelopmental disorders using a neurotrophic peptide (NNZ-2591).
This patent will supplement composition of matter patents in the U.S., Europe and Japan which have been granted until 2024, with the potential to extend expiry to 2029.
NNZ-2591 is a synthetic analog of the neurotrophic peptide cyclic glycine proline (cGP), which occurs naturally in the brain.
It has demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X syndrome, memory impairment and multiple sclerosis.
Furthermore, Neuren has confirmed that validation of the recently granted patent concerning the use of its lead molecule trofinetide to treat autism spectrum disorders has now been completed in Europe.
This, along with the U.S patent will strengthen the commercial exclusivity for both trofinetide and NNZ-2591, through a combination of composition of matter patents, method patents and orphan drug exclusivity periods.